A5073861459- Chronic Lymphocytic Leukemia Research
- Lymphoma Diagnosis and Treatment
- Microtubule and mitosis dynamics
- CAR-T cell therapy research
- Viral-associated cancers and disorders
- Acute Lymphoblastic Leukemia research
- Neutropenia and Cancer Infections
- Monoclonal and Polyclonal Antibodies Research
- Chronic Myeloid Leukemia Treatments
- Lung Cancer Treatments and Mutations
- CNS Lymphoma Diagnosis and Treatment
- Cancer Genomics and Diagnostics
- Cancer-related Molecular Pathways
- Synthesis and Biological Evaluation
- Cancer Treatment and Pharmacology
- Histone Deacetylase Inhibitors Research
- Gastrointestinal Tumor Research and Treatment
- Protein Degradation and Inhibitors
- Toxin Mechanisms and Immunotoxins
- Immune Cell Function and Interaction
- Ubiquitin and proteasome pathways
- T-cell and Retrovirus Studies
- Radiopharmaceutical Chemistry and Applications
- Multiple and Secondary Primary Cancers
- Phagocytosis and Immune Regulation
University of Arizona
2015-2024
University of Arizona Cancer Center
2014-2024
Banner - University Medical Center Tucson
2017-2022
Fred Hutch Cancer Center
2016-2020
University of Chicago
2016-2020
SWOG Cancer Research Network
2008-2020
University of Rochester
2016-2020
Oregon Health & Science University
2020
Hackensack University Medical Center
2017
Temple University
2017
Purpose To evaluate the effect of rituximab in limited-stage diffuse large B-cell lymphoma (DLBCL), we conducted a multicenter phase II trial combining with three cycles CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone; R-CHOP) followed by involved-field radiation therapy (IFRT). Patients Methods Southwest Oncology Group (SWOG) study S0014 enrolled patients newly diagnosed, aggressive, CD20-expressing non-Hodgkin's (NHL). had disease at least one adverse risk factor as...
Aurora A kinase (AAK) is overexpressed in aggressive lymphomas and can correlate with more histologically forms of disease. We therefore designed a phase II study alisertib, selective AAK inhibitor, patients relapsed refractory non-Hodgkin lymphomas.Patients age ≥ 18 years were eligible if they had or diffuse large B-cell lymphoma (DLBCL), mantle-cell (MCL), transformed follicular lymphoma, Burkitt's noncutaneous T-cell lymphoma. Alisertib was administered orally at 50 mg twice daily for 7...
Purpose Patients with double-hit lymphoma (DHL) rarely achieve long-term survival following disease relapse. Some patients DHL undergo consolidative autologous stem-cell transplantation (autoSCT) to reduce the risk of relapse, although benefit this treatment strategy is unclear. Methods who achieved first complete remission completion front-line therapy either rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) or intensive therapy, deemed fit for autoSCT, were...
Purpose Utility of combined-modality therapy for patients with limited-stage diffuse large B-cell lymphoma (DLBCL) was shown in the Southwest Oncology Group (SWOG) S8736 study, where three cycles CHOP (cyclophosphamide, doxorubicin, vincristine, and prednisone) plus radiotherapy (CHOP3RT) improved 5-year progression-free (PFS) overall survival (OS) compared eight (CHOP8). Subsequent analysis showed an unexpected overlap PFS curves. We aimed to confirm investigate this observation by...
Diffuse large B-cell lymphoma (DLBCL) presents as a limited-stage disease in 25% to 30% of patients, with better overall survival (OS) than that for advanced-stage but continuous relapse regardless treatment approach. The preferred is abbreviated rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) radiation therapy. On the basis promising results positron emission tomography (PET)-directed approaches, we designed National Clinical Trials Network (NCTN) study...
The targeting of mRNA and local protein synthesis is important for the generation maintenance cell polarity. As part translational machinery as well an actin/microtubule-binding protein, elongation factor 1alpha (EF1alpha) a candidate linker between translation apparatus cytoskeleton. We demonstrate in this work that EF1alpha colocalizes with beta-actin F-actin protrusions chicken embryo fibroblasts binds directly to simultaneously vitro actin cosedimentation enzyme-linked immunosorbent...
Background Translocations involving the MYC gene and increased mRNA levels are associated with poor outcome in diffuse large B-cell lymphoma. However, presence of copy number and/or polysomy chromosome 8 have not been previously described.Design Methods Utilizing dual color chromogenic situ hybridization, we investigated centromere numbers 52 cases Cases were divided into those "increased" or "not increased" for comparison levels, Ki-67 values, survival.Results Increased was present 38%...
This is the first report of Southwest oncology group phase II trial single agent bevacizumab in patients with relapsed, aggressive non-Hodgkin lymphoma (NHL). Fifty-two or second relapse diffuse large B-cell mantle cell were enrolled. Patients treated at 10 mg/kg every 2 weeks. Therapy was well tolerated no unexpected toxicities observed. Six-month progression-free survival (PFS) 16% a response rate 2% and median duration stable disease 5.2 months (range 3.5–72.7). Vascular endothelial...
Summary The oral BCL 2 inhibitor navitoclax has moderate single‐agent efficacy in chronic lymphocytic leukaemia ( CLL ) and minor activity lymphoma Phase 1 trials. Navitoclax synergizes with rituximab preclinical models of B‐cell lymphoid cancers. We report the safety, pharmacokinetics clinical this combination. Patients received (200–325 mg) daily four standard weekly doses rituximab. Twenty‐nine patients were enrolled across three dose‐escalation cohorts a safety expansion cohort (250 mg/d...
Abstract BACKGROUND: Patients with peripheral T‐cell lymphomas (PTCLs) have inferior progression‐free survival (PFS) and overall (OS) compared patients who aggressive B‐cell non‐Hodgkin lymphoma. Because PTCLs over express multidrug resistance gene 1/P‐glycoprotein (MDR‐1/P‐gp), we devised platinum, etoposide, gemcitabine, methylprednisolone (PEGS) agents that are not substrates of the efflux pump. Gemcitabine was included because its excellent single‐agent activity in PTCL. METHODS: had...
BACKGROUND Most patients with chronic lymphocytic leukemia (CLL) present multiple comorbidities. Although comorbidities negatively affect outcomes for treated chemoimmunotherapy, their impact on who receive targeted therapies is unknown. METHODS This multicenter, retrospective analysis evaluated the significance of comorbidities, as assessed by Cumulative Illness Rating Scale (CIRS), among CLL ibrutinib. RESULTS One hundred forty‐five received ibrutinib (80% in a relapsed/refractory...
BackgroundThe proliferative index (PI) is a powerful prognostic factor in mantle cell lymphoma (MCL); however, its utility hampered by interobserver variability. The international (MIPI) has been reported to have importance. In this study, we determined the value of PI as quantitative image analysis MCL.Patients and methodsEighty-eight patients with adequate tissue were included analysis. Patients treated one two treatment programs: sequential therapy high-dose consolidation or...
Diffuse large B-cell lymphoma (DLBCL), the most common form of non-Hodgkin's (NHL) diagnosed in USA, consists at least two distinct subtypes: germinal centre B (GCB) and activated (ABC). Decreased MHC class II (MHCII) expression on tumours both DLBCL subtypes directly correlates with significant decreases patient survival. One mechanism accounting for MHCII down-regulation is reduced transactivator (CIITA), master regulator transcription. Furthermore, CIITA ABC presence transcriptional...
Background Fc gamma receptor polymorphisms were linked to outcome in follicular lymphoma patients treated with single-agent rituximab, an anti-CD20 monoclonal antibody. In particular, 158F/F genotype of 3A and 131R/R 2A correlated worse compared high-affinity 158V/V 131H/H, respectively. We examined this association the context antibody combined chemotherapy, as chemotherapy alone, on SWOG clinical trials.Design Methods Tissue from 142 alone (protocol S8809, n=70) or (rituximab Iodine I-131...
Loss of major histocompatibility Class II expression (MHCII) in diffuse large B-cell lymphoma (DLBCL) correlates with decreased survival. MHCII transcription is part regulated by histone acetylation. We tested the hypothesis that combination deacetylase inhibitor (HDACI) standard chemotherapy would improve outcomes DLBCL through increased expression. S0806 was a single arm phase I/II trial vorinostat given at 400 mg po daily on days 1-9 (subsequently amended to 1-5 due toxicity), combined...
Targeted therapies and checkpoint blockade therapy (CBT) have shown efficacy for patients with Hodgkin lymphoma (HL) in the relapsed refractory (R/R) setting, but once discontinued owing to progression or side effects, it is unclear how successful further will be. Moreover, there are no data on optimal sequencing of these treatments standard other novel agents. In a multicenter, retrospective analysis, we investigated whether exposure CBT could sensitize HL subsequent therapy.Seventeen...
Abstract Purpose: Comorbid medical conditions define a subset of patients with chronic lymphocytic leukemia (CLL) poor outcomes. However, which comorbidities are most predictive remains understudied. Experimental Design: We conducted retrospective analysis from 10 academic centers to ascertain the relative importance assessed by cumulative illness rating scale (CIRS). The influence specific on event-free survival (EFS) was in this derivation dataset using random forests construct...